抗因子VIII非中和抗体与重型血友病A患者抑制剂开发风险
本研究基于SIPPET试验中237例未接受或极少接受FVIII浓缩物治疗的重型血友病A患者,在暴露前检测抗FVIII非中和抗体(NNA)。筛查时18例(7.6%)存在NNA,其抑制剂累积发生率为45.4%(95%CI 19.5%-71.3%),无NNA者为34.0%(95%CI 27.1%-40.9%);Cox回归显示NNA阳性者抑制剂发生率增高83%(HR 1.83,95%CI 0.84-3.99),高滴度抑制剂HR 2.74(95%CI 1.23-6.12)。
要点
- 筛查时7.6%(18/237)的重型血友病A患者存在抗FVIII非中和抗体,且呈明显年龄梯度。
- NNA阳性者抑制剂累积发生率为45.4%,NNA阴性者为34.0%。
- NNA阳性者抑制剂发生风险增高83%(HR 1.83,95%CI 0.84-3.99),高滴度抑制剂风险增高近三倍(HR 2.74,95%CI 1.23-6.12)。
核心结论
- 在未暴露于FVIII浓缩物的重型血友病A患者中,抗FVIII非中和抗体的存在与抑制剂发生率增高相关。
研究设计与样本
- 研究纳入SIPPET试验中237例重型血友病A患者,均为未接受或极少接受FVIII浓缩物治疗者,在暴露前采集血浆样本检测抗FVIII非中和抗体,并随访抑制剂发生。
主要发现
- 筛查时18例(7.6%)检出非中和抗体,且存在明显年龄梯度;非中和抗体阳性者中7例后续发生抑制剂,累积发生率为45.4%(95%CI 19.5%-71.3%)。
- 非中和抗体阴性者219例中64例(29%)发生抑制剂,累积发生率为34.0%(95%CI 27.1%-40.9%)。
- Cox回归分析中,非中和抗体阳性者抑制剂发生率较阴性者增高83%(HR 1.83,95%CI 0.84-3.99);高滴度抑制剂的HR为2.74(95%CI 1.23-6.12)。
- 上述关联经调整后无实质性改变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The development of anti-factor VIII (FVIII) neutralizing antibodies (inhibitors) is the major complication in hemophilia A. Nonneutralizing antibodies (NNAs) have been detected in hemophilia patients and also in unaffected individuals. The aim of this study was to assess the prevalence of NNAs and to evaluate whether their presence is associated with the development of inhibitors in a cohort of previously untreated or minimally treated patients with hemophilia A; plasma samples of 237 patients with severe hemophilia A enrolled in the SIPPET trial were collected before any exposure to FVIII concentrates and analyzed for the presence of anti-FVIII NNAs. Patients were observed for the development of neutralizing antibodies. NNAs were found in 18 (7.6%) of 237 patients at screening, and there was a clear age gradient. Of those with NNAs, 7 patients subsequently developed an inhibitor for a cumulative incidence of 45.4% (95% confidence interval [CI], 19.5% to 71.3%); among the 219 patients without NNAs, 64 (29%) developed an inhibitor (cumulative incidence, 34.0%; 95% CI, 27.1%-40.9%). In Cox regression analyses, patients with NNAs at screening had an 83% higher incidence of inhibitor development than patients without NNAs (hazard ratio [HR], 1.83; 95% CI, 0.84-3.99). For high-titer inhibitors, the incidence rate had an almost threefold increase (HR, 2.74; 95% CI, 1.23-6.12). These associations did not materially change after adjustment. The presence of anti-FVIII NNAs in patients with severe hemophilia A who were not previously exposed to FVIII concentrates is associated with an increased incidence of inhibitors.
引用
- Cannavò A, Valsecchi C, Garagiola I, et al. Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A. Blood. 2016. PMID: 28034891. doi:10.1182/blood-2016-06-720086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。